论文部分内容阅读
目的探讨药物敏感度检测对普外科常见肿瘤化疗的指导作用。方法分析收治的恶性肿瘤患者临床资料,依据是否实施药物敏感度检测将肿瘤患者分为观察组(20例)和对照组(20例)。结果核苷酸切除修复交叉互补基因1mRNA(ERCC1mRNA)高表达与铂类耐药有关,核糖核苷酸还原酶M1mRNA(RRM1mRNA)高表达与吉西他滨耐药有关,微管蛋白β3mRNA(TUBB3mRNA)高表达和抗微管类药物耐药有关。观察组患者化疗后生活质量明显高于对照组,而不良反应低于对照组,差异均有统计学意义(P<0.05)。结论药物敏感度检测在常见肿瘤化疗方案选定前的应用,不仅可以提高临床治疗效果,同时可以避免无效的化疗用药所导致的不良反应。
Objective To investigate the role of drug sensitivity testing in the treatment of common oncology chemotherapy in general surgery. Methods The clinical data of malignant tumor patients were analyzed. Tumor patients were divided into the observation group (20 cases) and the control group (20 cases) according to whether the drug sensitivity test was performed or not. Results The high expression of ERCC1mRNA was related to the resistance to platinum resistance. The high expression of ribonucleotide reductase M1mRNA (RRM1mRNA) was associated with the resistance to gemcitabine and the high expression of tubulinβ3mRNA (TUBB3mRNA) Anti-microtubule drug resistance related. The quality of life of the observation group was significantly higher than that of the control group after chemotherapy, but the adverse reaction was lower than that of the control group (P <0.05). Conclusion The application of drug sensitivity test before the selection of common cancer chemotherapy regimens not only can improve the clinical curative effect, but also avoid the adverse reactions caused by invalid chemotherapy.